KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Ratio (2016 - 2025)

Emergent BioSolutions' Equity Ratio history spans 16 years, with the latest figure at 0.4 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 14.08% year-over-year to 0.4; the TTM value through Dec 2025 reached 0.4, up 14.08%, while the annual FY2025 figure was 0.4, 14.08% up from the prior year.
  • Equity Ratio reached 0.4 in Q4 2025 per EBS's latest filing, down from 0.4 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.56 in Q1 2022 to a low of 0.26 in Q2 2024.
  • Average Equity Ratio over 5 years is 0.43, with a median of 0.4 recorded in 2023.
  • Peak YoY movement for Equity Ratio: crashed 41.93% in 2024, then skyrocketed 48.25% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.54 in 2021, then decreased by 19.56% to 0.44 in 2022, then dropped by 18.74% to 0.36 in 2023, then fell by 2.45% to 0.35 in 2024, then increased by 14.08% to 0.4 in 2025.
  • Per Business Quant, the three most recent readings for EBS's Equity Ratio are 0.4 (Q4 2025), 0.4 (Q3 2025), and 0.38 (Q2 2025).